Top Page
Tsumura & Co
(4540)
Tsumura & Co (4540) vs. iShares MSCI Japan ETF (EWJ)
Tsumura & Co Business Overview & Revenue Model
Tsumura & Co Financial Statement Overview
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 189.50B | 181.09B | 150.84B | 140.04B | 129.55B | 130.88B |
| Gross Profit | 90.20B | 90.58B | 68.82B | 68.28B | 66.47B | 74.93B |
| EBITDA | 54.61B | 57.25B | 34.82B | 33.89B | 31.57B | 28.00B |
| Net Income | 29.01B | 32.43B | 16.71B | 16.48B | 18.84B | 15.33B |
Balance Sheet | ||||||
| Total Assets | 549.68B | 464.38B | 428.25B | 396.81B | 350.98B | 319.06B |
| Cash, Cash Equivalents and Short-Term Investments | 69.48B | 73.23B | 78.08B | 94.75B | 67.55B | 61.31B |
| Total Debt | 135.41B | 70.34B | 79.69B | 79.69B | 49.69B | 52.85B |
| Total Liabilities | 211.04B | 134.27B | 132.89B | 124.57B | 92.87B | 85.89B |
| Stockholders Equity | 305.33B | 300.53B | 270.80B | 252.04B | 239.77B | 217.78B |
Cash Flow | ||||||
| Free Cash Flow | -21.99B | 6.23B | -14.45B | 1.74B | 10.73B | 6.69B |
| Operating Cash Flow | 15.40B | 33.82B | 5.61B | 16.45B | 21.31B | 16.10B |
| Investing Cash Flow | -46.44B | -24.97B | -19.35B | -15.49B | -9.11B | -7.35B |
| Financing Cash Flow | 20.41B | -19.87B | -4.42B | 24.42B | -8.18B | -10.43B |
Tsumura & Co Technical Analysis
Tsumura & Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥159.74B | -44.66 | 0.44% | 4.16% | -5.99% | -96.04% | |
77 Outperform | ¥346.47B | 11.61 | ― | 2.12% | 4.07% | 22.59% | |
73 Outperform | ¥439.97B | 21.79 | 7.11% | 2.43% | 3.53% | 38.23% | |
73 Outperform | ¥134.92B | 21.89 | 5.11% | 2.34% | 4.35% | 48.30% | |
69 Neutral | ¥320.57B | 10.81 | 9.05% | 3.30% | 10.51% | 9.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥18.69B | -9.94 | ― | 3.65% | 9.53% | -155.76% |
Tsumura & Co Corporate Events
Tsumura & Co. released supplementary materials for the third quarter of the fiscal year ending March 31, 2026, detailing consolidated financial statements, sales by business and product group, and quarterly performance data, with a particular focus on the sales and growth of 129 prescription Kampo formulations. The company also announced changes in its consolidation scope and reporting format, notably shifting to consolidate first the balance sheet and now, from the third quarter, the income statement of its Shanghai Hongqiao traditional Chinese drug pieces subsidiary, a move that is likely to provide a more complete view of the group’s financial position and performance and may underscore the growing strategic importance of its Chinese herbal medicine operations within the overall business.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen4584.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. reported consolidated net sales of ¥145.2 billion for the first nine months of the fiscal year ending March 31, 2026, a 6.1% year-on-year increase, but saw declines in profitability, with operating profit down 10.9%, ordinary profit down 9.2%, and profit attributable to owners of parent falling 12.9% to ¥23.2 billion; basic earnings per share dropped to ¥309.60 and the equity ratio weakened to 55.5% as total assets expanded. Despite the profit pressures, the company maintained its dividend policy with an interim payout of ¥68 per share and is forecasting a slight increase in the full-year dividend to ¥144 per share, while keeping its full-year guidance unchanged at ¥198.0 billion in net sales and a 25.1% decline in profit attributable to owners of parent, signaling a cautious stance amid rising costs or other margin challenges but continued commitment to shareholder returns.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen4584.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. clarified that recent reports in the digital and print editions of The Nikkei about its involvement in a potential take-private transaction for Yomeishu Seizo Co., Ltd. did not originate from the company itself. The company acknowledged that it is considering the reported matters but emphasized that no decisions have been made, and it pledged to disclose any material developments in a timely and appropriate manner, signaling that discussions remain at a preliminary stage and that stakeholders should not assume a finalized deal.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen4584.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. has entered into a large unsecured syndicated loan agreement with a bank group led by MUFG Bank to finance active investment in equipment and business initiatives tied to its long-term management vision, including sustaining growth in its domestic operations and expanding its presence in China. The agreement, split into two tranches totaling ¥50 billion and maturing in 2033 and 2036, includes financial covenants requiring the company to maintain at least 75% of specified consolidated net asset levels and to avoid recording operating losses for two consecutive fiscal years, underscoring both the lender’s risk controls and the company’s commitment to financial discipline, although Tsumura says the deal will have no material impact on its current earnings outlook.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen4226.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. has completed the acquisition of a 51% stake in Shanghai Hongqiao Traditional Chinese Drug Pieces Co., Ltd., a company specializing in pharmaceutical production and traditional Chinese medicine services. This acquisition is expected to be reflected in Tsumura’s financial statements from the mid-term period of the fiscal year ending March 2026, potentially impacting the company’s earnings and dividend forecasts.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen3870.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. has revised its Medium-Term Management Plan for FY2025-FY2027, increasing its operating profit and ROE targets due to better-than-expected business performance. The upward revision is driven by the consolidation of Shanghai Hongqiao Traditional Chinese Drug Pieces Co., Ltd., cost reductions, and effective expense management, positioning the company for improved financial outcomes despite inflationary pressures.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen3870.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. has revised its earnings and dividend forecasts for the fiscal year ending March 31, 2026, due to recent performance trends and strategic acquisitions. The company expects a 5.3% increase in net sales, primarily driven by the consolidation of Shanghai Hongqiao Traditional Chinese Drug Pieces Co., Ltd. Although operating profit is projected to rise by 49.8%, the impact of the acquisition is expected to be minor due to associated costs. The company has also increased its annual dividend forecast by 8 yen per share, reflecting improved profitability and a commitment to shareholder returns.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen3870.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. reported a slight increase in net sales for the six months ending September 30, 2025, but experienced significant declines in operating and ordinary profits compared to the previous year. Despite these challenges, the company has revised its dividend forecast upwards, indicating confidence in future performance. The financial results reflect a challenging period with decreased profitability, yet the company’s strategic adjustments, including dividend revisions, suggest a focus on long-term stability and growth.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen3870.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.